

References

I-124

1. Navada SC and Silverman LR. Safety and efficacy of azacitidine in elderly patients with intermediate to high-risk myelodysplastic syndromes. *Ther Adv Hematol*. 2017;8(1):21-27. Accessed February 21, 2018.
2. Murakami K, Ueno H, Okabe T, Kagoo T, Boku S, Yano T, et al. Bridging-to-transplant with azacitidine for myelodysplastic syndrome and acute myeloid leukemia, reduces the incidence of acute graft-versus-host disease. *Hematology Reports*. 2017;9:78-80. Accessed February 22, 2018.
3. Shapiro RM and Lazo-Langer A. Systematic review of azacitidine regimens in myelodysplastic syndrome and acute myeloid leukemia. *BMC Hematology*. 2018;18(3):1-9. Accessed February 22, 2018.
4. Pleyer L, Burgstaller S, Stauder R, Girschikofsky M, Sill H, Schlick K, et al. Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukemia: comparison of French-American-British and World Health Organization classifications. *Journ of Hemat & Onc*. 2016;9(39):1-16. Accessed February 23, 2018.
5. National Comprehensive Cancer Network (NCCN). Azacitidine. NCCN Drugs and Biologics Compendium®. Accessed February 15, 2018.
6. Azacitidine (Vidaza®) for subcutaneous or intravenous use [package insert]. Summit, NJ, Celgene Corporation. Revised 08/2016.
7. Azacitidine. Clinical Pharmacology Compendia. Tampa FL: Gold Standard, Inc. 2018.
8. Azacitidine. Micromedex®Solutions Compendia. 2018.